HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India

Tewari, Mallika; Kumar, A. V. Praveen; Rr, Mishra; Kumar, Mohan; Shukla, H. S.

doi:10.1007/s12262-013-0871-y

Cited by 16 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A review of the literature shows a decreased percentage of HER2/neu overexpression in the diffuse types of gastric cancers rather than absent expression. The present study and study by Rajagopal 10,15,16,19 In the present study as per CAP grading, HER2/neu positivity was found in 50% of well-differentiated and 36.4% of moderately differentiated tumors with none of the poorly differentiated tumors expressing HER2/neu and this was statistically highly significant with p value <0.01 and indicating that better-differentiated tumors showed HER2/neu overexpression. The findings of the present study are in concordance with the other studies in that HER2/neu expression is more in well and moderately differentiated tumors in comparison to poorly differentiated tumors (Table 7).…”

Section: Discussionsupporting

confidence: 60%

“…An exception to this is the study by Tewari M et al, which shows the total absence of HER2/neu expression in well-differentiated tumors. 19 This could probably be explained by the fact that only 3 out of 70 cases were well-differentiated tumors in that study. Similar to the present study another study from South India by Rajagopal I et al, shows a complete absence of HER2/neu expression in poorly differentiated tumors which could probably be explained by a geographical variation in gastric cancer epidemiology within India.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

HER2/neu immunohistochemical expression in gastric carcinoma

Sadanandan¹,

Arunraj²

2020

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Gastric carcinoma is a deadly disease with high mortality. A better understanding of the molecular basis of gastric cancer has contributed to the development of rationally designed molecular targeted therapies which will improve the survival rate. A genetic alteration that could help in targeted therapy and prognostication includes Human Epidermal Growth Factor Receptor 2 (HER2/neu) overexpression in gastric carcinoma. The objective of the present study was to identify and evaluate the HER2/neu protein immunohistochemical expression in gastric cancer from biopsies and surgical resection specimens and to evaluate their correlation with histopathological features.Methods: Total/subtotal gastrectomy specimens and gastric biopsies from a tertiary care center in South India were included in the study and assessed by light microscopy and Immunohistochemistry (IHC).Results: HER2/neu overexpression was seen in 28.6% of gastric adenocarcinoma. HER2/neu overexpression was seen in 44.2% of intestinal-type and 20% of mixed type with none of the diffuse type exhibited HER2/neu positivity and this was statistically highly significant with p value of <0.01. HER2/neu positivity was found in 50% well-differentiated and 36.4% moderately differentiated tumors with none of the poorly differentiated tumors exhibiting HER2/neu positivity and this was statistically highly significant with p value of <0.01.Conclusions: This study highlights the importance of the identification of HER2/neu overexpression in gastric adenocarcinoma. This will help in prognostication and identifying patients suitable for novel therapeutic interventions which will help in prolongation of survival of patients with this deadly disease.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Discussionmentioning

confidence: 74%

HER2/neu immunohistochemical expression in gastric carcinoma

Sadanandan¹,

Arunraj²

2020

Int J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…Park et al, [25] n= 182 Korea 16 Lordick et al, [7] n= 1527 Europe, Asia, Latin America [7][8][9][10]25] normal epithelium and Tumour cells and this did not interfere with our interpretation, one need to be careful during interpretation of HER2 staining. Intense cytoplasmic positivity (probably related to cytoplasmic mucin) in the Tumour cells though considered non -specific in the study, needed FISH confirmation because strong cytoplasmic staining can mask membranous positivity [30].…”

Section: Discussionmentioning

confidence: 99%

“…Evaluated extensively in breast cancers, the role of HER 2 over-expression in gastric adenocarcinomas is being studied. With few reports from India [8][9][10] and none from southern part of India, we attempted to study the same at a medical college hospital based in Bengaluru.…”

Section: Introductionmentioning

confidence: 99%

HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas

Rajagopal¹

2015

JCDR

View full text Add to dashboard Cite

Introduction: Gastric cancer is one of the leading causes of cancer mortality in the world/India with majority being diagnosed at an advanced stage. Various chemotherapeutic regimens have modestly improved overall survival leading to quest for novel therapeutic agents. Overexpression of HER2 in many gastric cancers has lead to the advent of targeted therapy with anti HER2 antibody like Trastusumab which has improved the overall survival. Materials and Methods:Sixty cases of gastric adenocarcinomas (44 biopsies and 16 gastrectomies) over the past five years ( June 2009 to June 2014),were included in the study. Diagnosis was confirmed by review of slides and IHC with anti HER2 antibodies was performed using Dako Real Envision Detection system and scoring was done by Hoffmann et al., scoring system. Results:Of the 60 cases, majority were males (60%),with a mean age of 65.65 yrs. Tumours in antrum (76.7%) formed the major bulk. HER2 expression was observed in 26.7% of Tumours, predominantly in males (p=0.006) and intestinal type (p= 0.054). HER2 expression correlated with Tumour grade (moderately differentiated and well differentiated, p= 0.042). Tumours of gastro-esophageal junction (GEJ) showed HER2 expression in 45.5% as opposed to 22.4% in gastric location. Poorly differentiated and diffuse type of adenocarcinomas did not express HER2. Two of three Tumours from patients in the age group 31-40 y expressed HER2. Conclusion:Male gender, intestinal-type and moderately differe ntiated gastric cancers may be the ones that can be targeted for therapy using Herceptin. Though trastusumab is approved for advanced gastric and GEJ cancers, it's role in adjuvant / neo-adjuvant setting in early stages needs to be evaluated with newer agents like Pertuzumab, Bevacizumab, especially in young patients. AIMS AND OBJECTIVES• To examine the frequency of expression of HER2 in primary gastric and gastro-esophageal junction(GEJ) adenocarcinoma.• To find its correlation with clinic-pathological parameters like age ,sex, location of Tumour, histological grade, Lauren classification, p TNM staging and H. pylori status. MATERIAlS AND METhODSThis was an observational study including all histopathologically diagnosed adenocarcinomas of stomach and gastro esophageal junction (GEJ) which were diagnosed in the Department of Pathology, Kempegowda Institute of Medical Sciences, Bengaluru over a period of five years (from June 2009 to June 2014).Relevant clinical details were collected from the patients' and case files in prospective cases (29 cases), while available details were collected from the medical records in retrospective cases (31 cases). Radiological and endoscopy details were retrieved wherever possible. All gastrectomy/gastric biopsy specimens were fixed in 10% neutral buffered formalin. Tissues were processed, embedded in paraffin, sections were taken and stained with routine H&E. Histopathological diagnosis was made and adenocarcinomas were classified as intestinal / diffuse according to Lauren classification. Giemsa stain...

show abstract

“…The methods of immunohistochemical analysis was used by the ToGA (Trastuzumab for gastric cancer) trial and also this method was adopted by the National Comprehensive Cancer Network guidelines version 2.201 [12,13] . The procedure for…”

Section: Immunohistochemical Analysismentioning

confidence: 99%

Detection of HER2 expression and its structural alterations in gastric cancer tissues infected with cagA+H. pylori

Srivastava¹,

Singh

2020

Preprint

View full text Add to dashboard Cite

Background: Helicobacter pylori (HP) cagA is the causing agent for development of gastric cancer (GC). H. pylori also involves to trigger the EGFR (epidermal growth factor receptor) expression in gastric cancer cells. However, the prognostic relation of cagA with HER2 status in GC was not well understood. Objective:The main aim of this study was to investigate the link of HER2 expression with CagA+ H. pylori in GC tissues. Materials and Methods:The study was performed on 85 GC tissues of GC patients.The specific primers of 16S rDNA and cagA for PCR amplification were used. For investigation of HER2 status in GC tissues, immunohistochemistry and PCR amplification were performed. In silico study was performed for the investigation of interactive potential of HER2 with CagA protein. Results: PCR amplified the 54 (63.52 %) of 85 GC tissues for HP that showed 34 (62.96 %) cagA+ HP. Immunohistochemistry of tissues revealed 57 (67.05 %) diffuse and 28 (32.94 %) intestinal type cancer. Of 85 cases, 21 GC tissues scored (2 + or 3 +) for positive HER2 expression and score (0 or 1 +) of 64 (75.29 %) showed negative. Of 21 HER2 + GC tissue, 15 biopsies had cagA+ HP and 2 were negative. PCR amplified single amplicon in 17 (20 %) CagA+ tissues and 3 (5.55 %) in CagA -HP. The molecular interactions of CagA was also showed its efficiency for HER2 expression. Conclusion:The study concluded that CagA+ HP may induce HER2 overexpression in GC tissues.

show abstract

HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India

Cited by 16 publications

References 28 publications

HER2/neu immunohistochemical expression in gastric carcinoma

HER2/neu immunohistochemical expression in gastric carcinoma

HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas

Detection of HER2 expression and its structural alterations in gastric cancer tissues infected with cagA+H. pylori

Contact Info

Product

Resources

About